[go: up one dir, main page]

DK3578201T3 - Fremgangsmåder og sammensætninger til naturlige dræberceller - Google Patents

Fremgangsmåder og sammensætninger til naturlige dræberceller Download PDF

Info

Publication number
DK3578201T3
DK3578201T3 DK19175670.9T DK19175670T DK3578201T3 DK 3578201 T3 DK3578201 T3 DK 3578201T3 DK 19175670 T DK19175670 T DK 19175670T DK 3578201 T3 DK3578201 T3 DK 3578201T3
Authority
DK
Denmark
Prior art keywords
compositions
methods
natural killer
killer cells
cells
Prior art date
Application number
DK19175670.9T
Other languages
English (en)
Inventor
Alicja Copik
Vijay Reddy
Jeremiah Oyer
Original Assignee
Univ Of Central Florida Research Foundation Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Of Central Florida Research Foundation Incorporated filed Critical Univ Of Central Florida Research Foundation Incorporated
Application granted granted Critical
Publication of DK3578201T3 publication Critical patent/DK3578201T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/80—Undefined extracts from animals
    • C12N2500/84—Undefined extracts from animals from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
DK19175670.9T 2012-06-28 2013-06-28 Fremgangsmåder og sammensætninger til naturlige dræberceller DK3578201T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261665591P 2012-06-28 2012-06-28
EP13809630.0A EP2866834B1 (en) 2012-06-28 2013-06-28 Methods and compositions for natural killer cells

Publications (1)

Publication Number Publication Date
DK3578201T3 true DK3578201T3 (da) 2023-05-08

Family

ID=49783918

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19175670.9T DK3578201T3 (da) 2012-06-28 2013-06-28 Fremgangsmåder og sammensætninger til naturlige dræberceller

Country Status (16)

Country Link
US (5) US9623082B2 (da)
EP (3) EP4279579A3 (da)
AU (4) AU2013282353B2 (da)
CA (1) CA2877968A1 (da)
DK (1) DK3578201T3 (da)
ES (1) ES2943932T3 (da)
FI (1) FI3578201T3 (da)
HR (1) HRP20230424T1 (da)
HU (1) HUE061931T2 (da)
LT (1) LT3578201T (da)
PL (1) PL3578201T3 (da)
PT (1) PT3578201T (da)
RS (1) RS64172B1 (da)
SG (2) SG11201408697QA (da)
SI (1) SI3578201T1 (da)
WO (1) WO2014005072A1 (da)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201505858VA (en) 2013-01-28 2015-09-29 St Jude Childrens Res Hospital A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
ES2612918T3 (es) * 2013-07-10 2017-05-19 Miltenyi Biotec Gmbh Método para inducir la proliferación de células asesinas naturales por nanomatrices móviles
EP3143134B1 (en) 2014-05-15 2020-10-28 National University of Singapore Modified natural killer cells and uses thereof
EP3223856B1 (en) * 2014-10-27 2025-09-24 University of Central Florida Research Foundation, Inc. Methods and compositions for natural killer cells
EP3138905A1 (en) * 2015-09-04 2017-03-08 Miltenyi Biotec GmbH Method for natural killer cell expansion
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
KR20240042177A (ko) * 2016-10-05 2024-04-01 유니버시티 오브 센트럴 플로리다 리서치 파운데이션, 인코포레이티드 Nk 세포 및 항-pdl1 암 요법과 관련된 방법 및 조성물
US10300089B2 (en) * 2016-11-08 2019-05-28 University Of Central Florida Research Foundation, Inc. Methods for high scale therapeutic production of memory NK cells
US11696927B2 (en) * 2017-02-28 2023-07-11 University Of Central Florida Research Foundation, Inc. PM21 particles to improve bone marrow homing of NK cells
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
SG11201908492PA (en) 2017-03-27 2019-10-30 Nat Univ Singapore Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy
EP3601537A4 (en) 2017-03-27 2021-01-13 National University of Singapore STIMULATING CELL LINES FOR EX VIVO EXPANSION AND ACTIVATION OF NATURAL KILLER CELLS
KR20240132124A (ko) * 2017-05-25 2024-09-02 유니버시티 오브 센트럴 플로리다 리서치 파운데이션, 인코포레이티드 천연 살해 세포에 의해 사멸하는 종양 세포를 감작시키기 위한 신규한 종양용해 바이러스
EP3746095A4 (en) 2018-02-01 2021-04-21 Nkmax Co., Ltd. Method of producing natural killer cells and composition for treating cancer
CN111801348A (zh) 2018-02-09 2020-10-20 新加坡国立大学 活化性嵌合受体及其在自然杀伤细胞免疫疗法中的用途
DK3755347T3 (da) * 2018-02-21 2025-08-04 Univ Texas Universelle antigenpræsenterende celler og anvendelser deraf
EP3755349A4 (en) 2018-02-21 2021-11-17 Board of Regents, The University of Texas System PROCESS FOR ACTIVATION AND EXPANSION OF NATURAL KILLER CELLS AND THEIR USES
KR20200138741A (ko) 2018-04-02 2020-12-10 내셔널 유니버시티 오브 싱가포르 면역 세포에서 발현되는 막-결합 항-사이토카인 비-신호전달 결합제를 이용한 인간 사이토카인의 중화
WO2019241315A1 (en) 2018-06-12 2019-12-19 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
JP7560882B2 (ja) 2018-08-29 2024-10-03 ナショナル ユニヴァーシティー オブ シンガポール 遺伝子修飾免疫細胞の生存及び増加を特異的に刺激するための方法
CN109627342B (zh) * 2018-12-10 2022-12-06 苏州近岸蛋白质科技股份有限公司 应用于nk细胞培养的蛋白质、培养基配方组合及制备方法
WO2020123716A1 (en) 2018-12-11 2020-06-18 Obsidian Therapeutics, Inc. Membrane bound il12 compositions and methods for tunable regulation
BR112021013971A2 (pt) * 2019-01-24 2021-11-16 Univ Central Florida Res Found Inc Composições e métodos para estimular células natural killer
WO2020160009A1 (en) * 2019-01-28 2020-08-06 Rhode Island Council On Postsecondary Education Phlip® targeted delivery of potent cytotoxic compounds
WO2020160047A2 (en) * 2019-01-28 2020-08-06 Rhode Island Council On Postsecondary Education Phlip® peptide-mediated epitope tethering at cell surfaces
US20220128541A1 (en) * 2019-02-14 2022-04-28 Research Institute At Nationwide Children's Hospital Use of plasma membrane particles, liposomes, and exosomes to assay immune cell potency
EP3773918A4 (en) 2019-03-05 2022-01-05 Nkarta, Inc. ANTI-CD19 CHEMERIC ANTIGEN RECEPTORS AND THEIR USE IN IMMUNOTHERAPY
KR20210149251A (ko) 2019-03-08 2021-12-08 옵시디안 테라퓨틱스, 인크. 조율가능한 조절을 위한 인간 탄산 무수화효소 2 조성물 및 방법
EP3983538A1 (en) 2019-06-12 2022-04-20 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
WO2020252404A1 (en) 2019-06-12 2020-12-17 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
CA3142952A1 (en) * 2019-06-25 2020-12-30 City Of Hope Pdl1 positive nk cell cancer treatment
CN112391349B (zh) * 2019-08-19 2023-05-23 刘韬 滋养层细胞株及其制备方法和体外诱导扩增nk细胞的方法
US20230092895A1 (en) 2019-08-30 2023-03-23 Obsidian Therapeutics, Inc. Tandem cd19 car-based compositions and methods for immunotherapy
WO2021050789A1 (en) 2019-09-10 2021-03-18 Obsidian Therapeutics, Inc. Ca2-il15 fusion proteins for tunable regulation
CN112426438B (zh) * 2019-11-14 2023-12-05 上海鑫湾生物科技有限公司 用于调控酸性环境免疫应答的组合物、其制备方法和用途
CN113646435A (zh) * 2019-12-09 2021-11-12 南克维斯特公司 通过非抗生素依赖性阳性选择筛选表达多基因转基因的细胞克隆
KR20220139319A (ko) 2020-01-08 2022-10-14 옵시디안 테라퓨틱스, 인크. 조정 가능한 전사의 조절을 위한 조성물 및 방법
US20250339502A1 (en) * 2020-03-20 2025-11-06 Orgenesis Inc. Ribonucleases for treating viral infections
WO2021201677A1 (en) 2020-04-01 2021-10-07 Kiadis Pharma Intellectual Property B.V. Compositions and methods targeting influenza
WO2021201679A1 (en) 2020-04-01 2021-10-07 Kiadis Pharma Intellectual Property B.V. Compositions and methods targeting coronaviruses
WO2021251708A1 (ko) * 2020-06-09 2021-12-16 사회복지법인 삼성생명공익재단 Nk 세포의 활성화 및 증폭을 위해 유전적으로 조작된 세포주, 및 그의 용도
WO2022047419A1 (en) 2020-08-31 2022-03-03 City Of Hope Novel cell lines, methods of producing natural killer cells and uses thereof
WO2022150392A1 (en) 2021-01-05 2022-07-14 City Of Hope Natural killer cells engineered to reduce or eliminate cbl-b and uses thereof
KR20240036997A (ko) * 2022-09-14 2024-03-21 재단법인 한국마이크로의료로봇연구원 사이토카인 활성 강화된 자연살해세포 유래 엑소좀의 암 치료용 생물학적 조성물 및 이의 용도
CN117987365B (zh) * 2023-12-27 2024-08-06 常州市第一人民医院 一种裂亡前列腺癌细胞囊泡的工程化改造方法及其应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849452B1 (en) * 1998-03-03 2005-02-01 Institut Gustave Roussy Methods for activating natural killer (NK) cells and means for carrying out said methods
US20030022854A1 (en) * 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
ATE418340T1 (de) 1999-05-06 2009-01-15 Univ Wake Forest Zusammensetzungen und methoden zur identifikation von antigenen, die eine immunantwort hervorrufen
CN1317301C (zh) * 2000-09-14 2007-05-23 贝斯以色列护理医疗中心有限公司 Il－2－和il－15－介导的t细胞应答的调节
AU2002310122A1 (en) * 2001-05-25 2002-12-09 Human Genome Sciences, Inc. Chemokine beta-1 fusion proteins
US20030148454A1 (en) * 2001-11-02 2003-08-07 Trustees Of Boston University Virus-free vesicles for delivery of functional membrane bound proteins
WO2004098529A2 (en) * 2003-04-30 2004-11-18 Emory University Therapeutic compositions and vaccines by glycosyl-phosphatidylinositol (gpi)-anchored cytokines and immunostimulatory molecules
CN102172397B (zh) * 2003-08-21 2013-01-30 利普泰克有限公司 树突细胞的体内靶向
EP2633866A3 (en) * 2003-10-17 2013-12-18 Novo Nordisk A/S Combination therapy
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
WO2005070120A2 (en) * 2004-01-09 2005-08-04 Serologicals Investment Company, Inc. Cell culture media
WO2005124346A1 (en) * 2004-05-17 2005-12-29 The Board Of Trustees Of The University Of Illinois 4-1bb receptors are expressed on regulatory t-cells
WO2006050270A2 (en) 2004-11-02 2006-05-11 The Government Of The United States Of America As Represented By The Secretary Department Of Health & Human Services Compositions and methods for treating hyperproliferative disorders
CA2504279A1 (en) * 2005-04-15 2006-10-15 University Of Saskatchewan Materials and method of modulating the immune response using t helper-antigen presenting cells
JP5322653B2 (ja) * 2005-11-28 2013-10-23 ザイモジェネティクス， インコーポレイテッド Ｉｌ−２１アンタゴニスト
MX2008007292A (es) * 2005-12-08 2008-10-17 Univ Louisville Res Found Composiciones inmunoestimuladoras y metodos.
KR101615935B1 (ko) * 2007-12-14 2016-04-28 노보 노르디스크 에이/에스 인간 ｎｋｇ2ｄ에 대한 항체 및 그것의 용도
WO2010071836A1 (en) * 2008-12-19 2010-06-24 Inserm Il-15 mediated nk and t cell maturation
AR083044A1 (es) * 2010-09-27 2013-01-30 Regeneron Pharma Anticuerpos anti-cd48 y usos de los mismos
WO2012177788A1 (en) * 2011-06-20 2012-12-27 La Jolla Institute For Allergy And Immunology Modulators of 4-1bb and immune responses
WO2013177187A2 (en) * 2012-05-22 2013-11-28 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
WO2013175237A1 (en) 2012-05-24 2013-11-28 Ucl Business Plc Composition comprising a cd2 ligation agent and a nkg2d ligation agent

Also Published As

Publication number Publication date
LT3578201T (lt) 2023-05-25
AU2013282353A1 (en) 2015-02-12
EP2866834B1 (en) 2019-05-22
US20150190471A1 (en) 2015-07-09
FI3578201T3 (fi) 2023-05-05
US10874715B2 (en) 2020-12-29
RS64172B1 (sr) 2023-05-31
HUE061931T2 (hu) 2023-09-28
US20170319659A1 (en) 2017-11-09
AU2019200525A1 (en) 2019-02-14
US9623082B2 (en) 2017-04-18
US12280094B2 (en) 2025-04-22
EP4279579A3 (en) 2024-02-21
EP2866834A4 (en) 2015-12-09
EP3578201B1 (en) 2023-04-19
CA2877968A1 (en) 2014-01-03
US20200138908A1 (en) 2020-05-07
AU2013282353B2 (en) 2018-10-25
ES2943932T3 (es) 2023-06-16
PL3578201T3 (pl) 2023-09-11
PT3578201T (pt) 2023-05-10
US20190117736A1 (en) 2019-04-25
AU2024267081A1 (en) 2024-12-19
US20230321191A1 (en) 2023-10-12
WO2014005072A1 (en) 2014-01-03
AU2021202439A1 (en) 2021-05-13
EP3578201A1 (en) 2019-12-11
US10463715B2 (en) 2019-11-05
EP2866834A1 (en) 2015-05-06
SG11201408697QA (en) 2015-02-27
AU2021202439B2 (en) 2024-09-05
HRP20230424T1 (hr) 2023-07-07
SI3578201T1 (sl) 2023-06-30
US11617781B2 (en) 2023-04-04
AU2019200525B2 (en) 2021-01-21
SG10201610915XA (en) 2017-02-27
EP4279579A2 (en) 2023-11-22

Similar Documents

Publication Publication Date Title
DK3578201T3 (da) Fremgangsmåder og sammensætninger til naturlige dræberceller
IL264271A (en) Methods of generating natural killer cells
DK3421051T3 (da) Fremgangsmåder til glycokonjugering og sammensætninger
DK2929031T5 (da) Pcsk9-irna-sammensætninger og fremgangsmåder til anvendelse deraf
PL2884999T3 (pl) Sposób i kompozycje do immunoterapii komórkowej
DK2978419T3 (da) Sammensætninger til forbedring af cellelevedygtighed og fremgangsmåder til anvendelse deraf
DK3366143T3 (da) Probiotiske sammensætninger og fremgangsmåder
DK3628161T3 (da) Synergistiske bakterielle sammensætninger og fremgangsmåder til fremstilling og anvendelse deraf
DK3441468T3 (da) Afgivelsesfremgangsmåder og sammensætninger til nukleasemedieret genom-manipulation
DK2850202T3 (da) Fremgangsmåder og grupper
DK2763665T3 (da) Antimikrobielle sammensætninger og fremgangsmåder til anvendelse deraf
DK3080274T3 (da) Fremgangsmåder og sammensætninger til genom-manipulation
DK2857401T3 (da) Hidtil ukendt -lactamaseinhibitor og fremgangsmåde til at fremstille samme
DK2861223T3 (da) Sammensætninger og metoder til transmukosal absorption
DK2872153T3 (da) Accellulære pro-tolerogene sammensætninger og fremgangsmåde til fremstilling heraf
DK3008168T3 (da) Sc-celler og sammensætninger og fremgangsmåde til dannelse deraf
DK3495392T3 (da) Anti-cgrp-sammensætninger og anvendelse deraf
DK3468197T3 (da) Fremgangsmåde til interforudsigelse og indretning dertil
DK2678283T3 (da) Vanadiumbaserede frittematerialer og fremgangsmåder til deres fremstilling
DK2922955T3 (da) Sammensætninger og fremgangsmåder til modulering af FGFR3-ekspression
DK2830654T3 (da) Metoder og sammensætninger til behandling af inflammation
DK2600715T3 (da) Flydende ST-246-formuleringer og fremgangsmåder
DK2704744T3 (da) Komplementfaktor-b-analoger og anvendelser deraf
DK2896694T3 (da) Saccharidoxidase og fremgangsmåde til fremstilling deraf og anvendelse deraf
DK2854822T3 (da) Polysaccharidsammensætninger og fremgangsmåder til anvendelse